智通财经APP讯，心玮医疗-B(06609)公布，该集团预期于2025年上半年取得股东应占净利润不少于人民币4000万元，是次转亏为盈乃主要由于(i)新推出的出血性脑卒中治疗器械，及急性缺血性脑卒中治疗器械及其他出血性脑卒中治疗器械的销售增加带动收益增长;(ii)销售成本及行政成本的有效成本控制措施令集团整体费用率有所下降，及集团研发项目的研发阶段变动令研发开支减少;及(iii)按公允价值计入损益的金融资产公允价值收益增加。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.